Navigation Links
Echo Therapeutics Announces Closing of Approximately $2.3 Million Private Financing
Date:2/12/2008

FRANKLIN, Mass., Feb. 12 /PRNewswire-FirstCall/ -- Echo Therapeutics, Inc. (OTC Bulletin Board: ECTE), a specialty pharmaceuticals and diagnostics company, announced today that it had completed an approximately $2.3 million private financing with Montaur Capital through Platinum Long Term Growth VII, LLC and certain other select institutional and strategic investors of senior unsecured convertible notes and warrants.

The $2,292,459 in aggregate principal amount of Senior Convertible Notes to be issued in the financing will bear interest annually at a rate of 8.0% per annum and will provide investors with the right to convert principal into shares of Echo Therapeutics common stock at $1.35 per share. The conversion price is subject to weighted average anti-dilution protection, excluding certain customary exceptions. The notes have a three-year term and Echo may elect to make payments of interest in cash, additional notes, or stock.

Additionally, the investors received warrants to purchase 849,058 shares of common stock at an exercise price of $1.69 per share for a term of five years. The warrants provide for full anti-dilution protection to the holders and allow for cashless exercise.

In connection with the financing, certain holders of Echo's Senior Promissory Bridge Notes, dated as of September 14, 2007, exchanged their Bridge Notes at 120% of the outstanding principal and interest of the Bridge Note as payment toward the purchase price of the Senior Convertible Notes purchased by such holders. Accordingly, Echo issued notes in the financing in the aggregate principal balance of $1,592,459 to the former holders of the Bridge Notes upon their surrender of the Bridge Notes, and Echo received gross cash proceeds in the amount of $700,000 in connection with the financing.

Echo expects to use the net proceeds from the offering for product development, working capital and general corporate purposes.

The securities issued in the f
'/>"/>

SOURCE Echo Therapeutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine news :

1. Transition Therapeutics Announces Second Quarter Fiscal 2008 Financial Results
2. DARA BioSciences, Inc. and Point Therapeutics, Inc. Announce Consummation of Merger
3. Protalix BioTherapeutics Appoints Professor Roger D. Kornberg to Board of Directors
4. Transition Therapeutics to Hold Conference Call on Second Quarter Fiscal 2008 Financial Results on Tuesday, February 12, 2008 at 5:00 P.M. EST
5. Nile Therapeutics Announces Dosing of First Heart Failure Patient in Phase Ib Study of CD-NP
6. Cell Therapeutics, Inc. (CTI) Cuts Net Operating Expenses 35% and Expands Commercial Team to Support Zevalin(R) Sales and Applications Seeking Two Product Approvals in 2009
7. Prime Therapeutics Becomes First PBM to Join the Center for Health Value Innovation
8. Reckitt Benckiser Completes Acquisition of Adams Respiratory Therapeutics, Inc.
9. Nektar Therapeutics President and CEO, Howard W. Robin, to Present at Merrill Lynch 19th Global Pharmaceutical, Biotechnology & Medical Device Conference in New York City
10. Allos Therapeutics Appoints Bruce K. Bennett as Vice President, Manufacturing
11. Ocera Therapeutics Receives Orphan Drug Status for AST-120 for Pouchitis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/20/2014)... Santa Rosa, CA (PRWEB) August 20, 2014 ... is the 12 per diode panel band perfect spectrum that ... plants are most likely to use during photosynthesis. A ... spectral bands is that they almost exclusively reside between 440-480 ... 620-680 on the red side of the spectrum. The KIND ...
(Date:8/20/2014)... 2014 Get the report here: ... presents “Deal Drivers 2014 Half Year Report for the ... activity in both North and South America, with targeted ... Merrill DataSite     , Merrill DataSite is a secure ... due diligence process by providing a highly efficient and ...
(Date:8/20/2014)... (PRWEB) August 20, 2014 Understanding ... governmental and physician stakeholders networks impacting the launch ... America, US, Canada, and Emerging Markets. , This ... Experts’ perspectives on stakeholder management needs for the ... immunotherapy and targeted therapy investigational agents that are ...
(Date:8/20/2014)... Angeles, CA (PRWEB) August 20, 2014 ... it is bringing on Wrench Advisors as a ... tasks including international large accounts. , As Wrench ... sales consultants can help your organization plan and ... executives and global distribution channels. Our experience developing ...
(Date:8/20/2014)... Beach, Florida (PRWEB) August 20, 2014 ... Florida, with the help of their experienced surgeons trained ... of patients to regain their lost or inaccurate vision. ... for performing Lasik surgery is making it possible for ... aging disease which occurs normally in people in the ...
Breaking Medicine News(10 mins):Health News:Cheap LED Grow Lights Are Quickly Being Replaced by Premium Grow Lights 2Health News:Register to Download Merrill DataSite's Report: Deal Drivers 2014 Half Year Report for the Americas 2Health News:Download HeartBeat Experts White Paper: A Stakeholder Engagement Strategy is Critical for the Evolving Melanoma Treatment Setting 2Health News:Biocide Systems Announces Partnership with Wrench Advisors 2Health News:Braverman Eye Center Now Offers Multifocal PresbyLasik in Florida by Trained Surgeons 2
... August 2, 2009 The world,s top lung cancer ... in San Francisco, CA for the 13th World Conference ... for the Study of Lung Cancer (IASLC). Prevention and ... lung cancer remains one of the hardest cancers to ...
... , , , ... around the world are turning to cosmetic surgery in increasing numbers, ... "moobs" ("man boobs".) , , Male cosmetic surgery ... countries where the stigma attached to male cosmetic surgery has all ...
... , MINNEAPOLIS, July 28 Employees ... boots this week as the cooperative put in place a new ... to execute a voluntary recall of instant nonfat dried milk, whey ... new protocols for the dry ingredients production area in preparation for ...
... cell lung cancer (NSCLC) patients over the age of ... erlotinib, Fox Chase Cancer Center researchers reported today at ... Study of Lung Cancer. "Based on our initial ... efficacious, though we,ll have to wait and see the ...
... 1, 2009 The world,s top lung cancer specialists, ... San Francisco, CA for the 13th World Conference on ... the Study of Lung Cancer (IASLC). According to a ... therapies, as first-line treatment, have the potential to slow ...
... ... its entry into the interventional radiology marketplace with the nationwide launch of its new ... ... entry into the interventional radiology marketplace with the nationwide launch of its new ...
Cached Medicine News:Health News:Diagnostic tools and innovative therapies improve patient prognosis 2Health News:Diagnostic tools and innovative therapies improve patient prognosis 3Health News:Diagnostic tools and innovative therapies improve patient prognosis 4Health News:Diagnostic tools and innovative therapies improve patient prognosis 5Health News:Diagnostic tools and innovative therapies improve patient prognosis 6Health News:Men Around the World Seek Cosmetic Surgery 2Health News:Plainview Milk Products Cooperative Implements New Employee Boot Policy 2Health News:Fox Chase finds all-biologic regimen efficacious and well-tolerated in elderly lung cancer patients 2Health News:Advanced targeted therapies effective as first-line treatment for lung cancer 2Health News:Advanced targeted therapies effective as first-line treatment for lung cancer 3Health News:Advanced targeted therapies effective as first-line treatment for lung cancer 4Health News:Advanced targeted therapies effective as first-line treatment for lung cancer 5Health News:Advanced targeted therapies effective as first-line treatment for lung cancer 6Health News:Advanced targeted therapies effective as first-line treatment for lung cancer 7Health News:Advanced targeted therapies effective as first-line treatment for lung cancer 8Health News:New DrainEx(TM) Catheter Simplifies Insertion and Replacement 2
(Date:8/20/2014)... , August 20, 2014 ... Conducted in the US  KalVista Pharmaceuticals ("KalVista"), ... edema (DME), today announces that it has begun a ... plasma kallikrein inhibitor, KVD001, for the treatment of DME. ... of the Beetham Eye Institute, Joslin Diabetes Center; Harvard ...
(Date:8/19/2014)...  The Alabama Supreme Court, in a 6-3 decision on ... who mislead doctors into believing that prescription medicines the companies ... v. Wyeth, and the decision came after the Supreme Court ... year. Heninger Garrison Davis attorneys Lew Garrison and ... Danny Weeks . The decision won a ...
(Date:8/19/2014)... , Aug. 19, 2014  Northwest Biotherapeutics (NASDAQ: ... DCVax® personalized immune therapies for solid tumor cancers, announced ... last Thursday, August 14, 2014, has closed.  The three-year ... at $7.30 per share of common stock.  The investors ... purchase up to an additional 30% of these notes ...
Breaking Medicine Technology:KalVista Pharmaceuticals Announces Start of Clinical Development for Novel Treatment for Diabetic Macular Edema 2KalVista Pharmaceuticals Announces Start of Clinical Development for Novel Treatment for Diabetic Macular Edema 3KalVista Pharmaceuticals Announces Start of Clinical Development for Novel Treatment for Diabetic Macular Edema 4Heninger Garrison Davis Clients To Get Their Day in Court Against Brand Drug Companies 2Heninger Garrison Davis Clients To Get Their Day in Court Against Brand Drug Companies 3Heninger Garrison Davis Clients To Get Their Day in Court Against Brand Drug Companies 4NW BIO COMPLETES THE CLOSING OF ITS $17.5 MILLION CONVERTIBLE NOTE OFFERING 2NW BIO COMPLETES THE CLOSING OF ITS $17.5 MILLION CONVERTIBLE NOTE OFFERING 3
... Epiphany Biosciences announced,today, the initiation of a ... treatment and management of acute infectious,mononucleosis. Currently, there ... debilitating condition or any other disease caused by,the ... broad spectrum of anti-viral activity,including inhibition of viral ...
... SAN FRANCISCO, Calif., Dec. 6 Rigel,Pharmaceuticals, Inc. (Nasdaq: ... (NYSE: PFE ), has begun a Phase 1 ... syk kinase inhibitor, R343,for the treatment of allergic asthma. ... Under the terms of the companies, 2005 collaboration ...
Cached Medicine Technology:Epiphany Biosciences Reports Initiation of Phase 2 Study of Valomaciclovir for the Treatment of Acute Infectious Mononucleosis 2Rigel Announces Initiation of Phase 1 Clinical Trial of R343 for Allergic Asthma by its Partner Pfizer 2Rigel Announces Initiation of Phase 1 Clinical Trial of R343 for Allergic Asthma by its Partner Pfizer 3
... 1100RS Spectrophotometers are simple, ... for use in many ... educational, clinical, industrial and ... COD vial holders, Windows ...
Spectra 2000 Digital Spectrophotometer is designed for quantitative and qualitative analysis in visible range from 320 nm to 1020 nm....
... Series Spectrophotometer is truly ... UV-VIS instrumentation. The latest ... into a radically new ... and performance unprecedented in ...
... Darkfield Quebec Colony Counter allows the user ... choice of models allows for digital counting or ... over the standard lens increasing magnification to 3.0X. ... lens to be raised or lowered. The lens ...
Medicine Products: